This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

High Resolution 3D Diffusion-weighted Breast MRI

This study has suspended participant recruitment.
Information provided by (Responsible Party):
Stanford University Identifier:
First received: March 11, 2011
Last updated: October 24, 2016
Last verified: October 2016
The purpose of this study is to determine how well a new MRI technique called "High resolution 3D diffusion-weighted breast MRI" detects breast cancer.

Condition Intervention
Breast Cancer Metastatic Breast Cancer Device: Magnetic Resonance Image Scanner

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: High Resolution 3D Diffusion-weighted Breast MRI

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Sensitivity of the new MRI method [ Time Frame: 8 weeks ]
  • Lesion detection rate of the new MRI method [ Time Frame: 4 weeks ]

Estimated Enrollment: 500
Study Start Date: March 2011
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: Magnetic Resonance Image Scanner
    Magnetic Resonance Imaging; 1.5 Tesla or 3 Tesla MRI scanner
    Other Name: MRI
Detailed Description:
The objective of this study is to assess the diagnostic accuracy of a new non-contrast MRI method for breast cancer detection. The study design is a single arm observational study. The new technique will be added on to the standard sequences that a women undergoes during a breast MRI. The resulting images will be compared with her standard breast MRI images, and with results of subsequent pathology.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Stanford Radiology Department MRI facilities

Inclusion Criteria:1. Patient scheduled for contrast-enhanced breast MRI to image possible breast cancer.

2. Female

3. Age >18

Exclusion Criteria:1. Lactation

2. Pregnancy

3. Patient undergoing chemotherapy. These patients are excluded because chemotherapy changes the biology of breast cancers. Since the ultimate objective of the research is to develop a new imaging method for breast MRI screening (detection of previously unknown tumors), results in treated tumors would not be relevant. Including treated tumors could yield a misleading assessment of the performance of the new method since treated tumors have different imaging characteristics than de novo tumors.

4. Patient scheduled for pre-operative chemotherapy. These patients are excluded if they are going to be treated only on the basis of fine needle aspiration. The project seeks to correlate all tumors detected with standard histopathology of their untreated neoplasm. This exclusion criteria will be very unusual because most patients planning neoadjuvant chemotherapy do so on the basis of a pre-chemo core needle biopsy, which provide adequate histopathologic proof necessary for enrollment.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01315106

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Principal Investigator: Bruce L. Daniel Stanford University
  More Information

Responsible Party: Stanford University Identifier: NCT01315106     History of Changes
Other Study ID Numbers: BRS0013
SU-11152010-7211 ( Other Identifier: Stanford University )
19595 ( Other Identifier: Stanford IRB )
Study First Received: March 11, 2011
Last Updated: October 24, 2016

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases processed this record on August 18, 2017